A clinical-stage prostate cancer therapy with long-term human data.
A clinical-stage platform with long-term human follow-up, a brand-stable agent, and an IP estate built around the activation protocol, supported by Australian capital and regulatory advantages. ImmunoPDT is in active capital raise; specific figures are addressed in direct investor conversations under appropriate agreements.
One therapy with potential beyond prostate.
ImmunoPDT is a photodynamic therapy with potential across a range of solid tumours. We are starting with prostate cancer, the most clinically and commercially significant indication, and where the human evidence is deepest. The patent estate covers the agent class and the activation protocol.
Intellectual property
Granted Australian patent (AU 2021388872) plus an international PCT family (WO2022112537).
One therapy, multiple potential indications
The patent estate covers the agent class and the activation protocol, supporting forward-looking potential across a range of solid tumours.
A patent estate built around the agent and the activation protocol.
| Jurisdiction | Reference | Status | Key dates |
|---|---|---|---|
| Australia | AU 2021388872 | Granted | Priority 26 Nov 2020 · Expires 26 Nov 2041 |
| International (PCT) | WO2022112537 | National phase pending | Priority 26 Nov 2020 · Filed 26 Nov 2021 |
Held by the licensor, RMW Cho Group.
Platform scope
The protection covers the Immuno1 agent class and the ImmunoPDT activation protocol, not solely the current chemistry. Because it sits at the agent-class and protocol level, the Immuno1 brand can carry forward if the underlying compound is improved or substituted.
Licence chain
The patent family is held by the licensor (RMW Cho Group) and licensed through the ImmunoPDT corporate structure to the operating company that runs the prostate-cancer programme. The structure separates the broader platform rights from the prostate-specific operating field.
Built on Australian clinical discipline.
Australian pathways and capital efficiency
ImmunoPDT is built on Australian clinical discipline. Phase 2 is conducted under the Clinical Trial Notification (CTN) and Special Access Scheme (SAS) regulatory pathways, with TGA oversight. The R&D Tax Incentive and Early Stage Innovation Company (ESIC) status add meaningful capital efficiency for investors.
Forward roadmap
ImmunoPDT is in active development. Pre-FDA engagement and an EU regulatory pathway are part of the forward roadmap. The therapy is not approved for marketing in any jurisdiction.
- check_circle The clinical evidence summary, with sources.
- check_circle The mechanism and platform overview.
- check_circle The leadership and governance profile.
- check_circle The Australian capital and regulatory context.
- check_circle How to start a direct investor conversation.